Figure 2
Comparator and ibrutinib survival curves. (A) Modeled comparator overall survival (OS) and progression-free survival (PFS) curves compared with the published data. Illustration of the modeled survival curves for the comparator arm (red) compared with digitized data from the chlorambucil arm of RESONATE-2 trial7 (blue). Long-term survival curves for the modeled base case are available in supplemental Figure 1. (B) Modeled ibrutinib OS and PFS survival curves compared with the published data. Illustration of the modeled survival curves for the ibrutinib arm (purple) compared with digitized data from the ibrutinib arm of RESONATE-2 trial7 (orange). JSH, Japanese Society of Hematology.

Comparator and ibrutinib survival curves. (A) Modeled comparator overall survival (OS) and progression-free survival (PFS) curves compared with the published data. Illustration of the modeled survival curves for the comparator arm (red) compared with digitized data from the chlorambucil arm of RESONATE-2 trial (blue). Long-term survival curves for the modeled base case are available in supplemental Figure 1. (B) Modeled ibrutinib OS and PFS survival curves compared with the published data. Illustration of the modeled survival curves for the ibrutinib arm (purple) compared with digitized data from the ibrutinib arm of RESONATE-2 trial (orange). JSH, Japanese Society of Hematology.

Close Modal

or Create an Account

Close Modal
Close Modal